← Leaderboards
Edmund K. Waller
Emory University
$12,096,498
Attributed
$13,931,898
Total exposure
13
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,931,898 · 13
By mechanism
R01$8,175,062 · 4
P01$2,244,382 · 3
R44$1,404,992 · 1
M01$879,207 · 1
UG1$485,186 · 1
R56$378,687 · 1
Top collaborators
- Zaid Al-Kadhimi2 shared
- Gary G. Altman2 shared
- Jack W Hsu2 shared
- Gregory B. Lesinski2 shared
- Chrystal Mary Paulos2 shared
Most similar at Emory University
Same institution · by research overlap
- Hyunsuk Shim$7,356,562
- Leslie S Kean$43,609,566
- Gregory B. Lesinski$9,344,242
- Christian P Larsen$35,318,088
Others in their field
Top investigators on “T-Lymphocyte”
- Barton F Haynes · Duke University$296,833,570
- Lawrence Corey · Fred Hutchinson Cancer Center$270,341,865
- Dan H. Barouch · Fred Hutchinson Cancer Center$117,305,894
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$107,651,960
- Alessandro Sette · La Jolla Institute For Immunology$75,756,097
- Rama Rao Amara · Emory University$69,530,112
Research focus
T-LymphocyteClinical TrialsImmuneTransplantationAllogenicCellsImmunityHematopoietic Stem CellsBloodStem Cell TransplantPre-ClinicalCytokineHematopoietic Stem Cell TransplantationPublishingTransplant RecipientsIn VivoStem CellsPreclinical StudyBaseAffectT-Cell ActivationBone Marrow TransplantationLeadDendritic Cells
Grant awards (37)
Development of a Novel Immunotherapeutic for Acute Myeloid Leukemia$999,997
R44 · FY2025 · CA
Leveraging CD26high Meso-CAR T cells in patients with advanced pancreatic cancer$638,929
R01 · FY2025 · CA
BMT Core: Southeast Bone Marrow Transplant Consortium$228,194
UG1 · FY2025 · HL · contact PI
Using donor dendritic cells to optimize GvHD and GvL in allogeneic stem cell transplantation$624,469
R01 · FY2024 · AI · contact PI
Leveraging CD26high Meso-CAR T cells in patients with advanced pancreatic cancer$575,241
R01 · FY2024 · CA
Development of a Novel Immunotherapeutic for Acute Myeloid Leukemia$404,995
R44 · FY2024 · CA
BMT Core: Southeast Bone Marrow Transplant Consortium$256,992
UG1 · FY2024 · HL · contact PI
Using donor dendritic cells to optimize GvHD and GvL in allogeneic stem cell transplantation$740,533
R01 · FY2023 · AI · contact PI
Using donor dendritic cells to optimize GvHD and GvL in allogeneic stem cell transplantation$746,773
R01 · FY2022 · AI · contact PI
Using donor dendritic cells to optimize GvHD and GvL in allogeneic stem cell transplantation$756,133
R01 · FY2021 · AI · contact PI
Using donor dendritic cells to optimize GvHD and GvL in allogeneic stem cell transplantation$756,133
R01 · FY2020 · AI · contact PI
Using donor dendritic cells to optimize GvHD and GvL in allogeneic stem cell transplantation$378,687
R56 · FY2019 · AI · contact PI
Project 3: Red cell transfusions and donor T-cell activation in allo-stem cell t$311,332
P01 · FY2019 · HL · contact PI
Using donor pDC to optimize GvHD and GvL in allogeneic stem cell transplantation$323,700
R01 · FY2018 · CA · contact PI
Project 3: Red cell transfusions and donor T-cell activation in allo-stem cell t$318,236
P01 · FY2018 · HL · contact PI
Project 3: Red cell transfusions and donor T-cell activation in allo-stem cell t$333,140
P01 · FY2017 · HL · contact PI
Using donor pDC to optimize GvHD and GvL in allogeneic stem cell transplantation$323,700
R01 · FY2017 · CA · contact PI
Project 3: Red cell transfusions and donor T-cell activation in allo-stem cell t$341,996
P01 · FY2016 · HL · contact PI
Using donor pDC to optimize GvHD and GvL in allogeneic stem cell transplantation$323,700
R01 · FY2016 · CA · contact PI
Project 3: Red cell transfusions and donor T-cell activation in allo-stem cell t$377,121
P01 · FY2015 · HL · contact PI
Using donor pDC to optimize GvHD and GvL in allogeneic stem cell transplantation$323,700
R01 · FY2015 · CA · contact PI
Manufacturing pathogen inactivated platelet lysate to treat corneal inflammation$149,265
R41 · FY2015 · EY · contact PI
Using donor pDC to optimize GvHD and GvL in allogeneic stem cell transplantation$323,700
R01 · FY2014 · CA · contact PI
Modified Donor Lymphocytes Infusion (mDLI) for Rapid Immune Reconstitution$337,040
P01 · FY2011 · HL · contact PI
Immunologic and Virologic Monitoring Laboratory Core$225,517
P01 · FY2011 · HL · contact PI
CLINICAL TRIALS- SHARED RESOURCES$67,358
P30 · FY2011 · CA · contact PI
CLINICAL TRIALS- SHARED RESOURCES$77,094
P30 · FY2010 · CA · contact PI
CLINICAL TRIALS- SHARED RESOURCES$70,665
P30 · FY2009 · CA · contact PI
Separating Antitumor & GvHD in Allogeneic T-Cells$298,849
R01 · FY2007 · CA · contact PI
Separating Antitumor & GvHD in Allogeneic T-Cells$300,890
R01 · FY2006 · CA · contact PI
Separating Antitumor &GvHD in Allogeneic T-Cells$301,389
R01 · FY2005 · CA
Separating Antitumor &GvHD in Allogeneic T-Cells$294,842
R01 · FY2004 · CA
Separating Antitumor &GvHD in Allogeneic T-Cells$283,671
R01 · FY2003 · CA
ADOPTIVE TRANSFER OF IMMUNITY IN BONE MARROW TRANSPLANTATION$293,069
M01 · FY2002 · RR
ADOPTIVE TRANSFER OF IMMUNITY IN BONE MARROW TRANSPLANTATION$293,069
M01 · FY2002 · RR
ADOPTIVE TRANSFER OF IMMUNITY IN BONE MARROW TRANSPLANTATION$293,069
M01 · FY2001 · RR
ANTILEUKEMIC EFFECT OF IRRADIATED ALLOGENEIC LYMPHOCYTES$238,710
R01 · FY2000 · CA